Uta KiltzDésirée Van Der HeijdeAnnelies BoonenNurullah AkkocWilson Bautista-MolanoRuben Burgos-VargasJames Cheng Chung WeiPraveena ChiowchanwisawakitMaxime DougadosM. Tuncay DuruozBassel Kamal ElzorkanyInna GaydukovaLianne S. GenslerMichele GilioSimeon GrazioJieruo GuRobert D. InmanTae Jong KimVictoria Navarro-CompanHelena Marzo-OrtegaSalih OzgocmenFernando Pimentel Dos SantosMichael SchirmerSimon StebbingsFilip E. Van Den BoschAstrid Van TubergenJuergen BraunUniversidad Militar Nueva GranadaChung Shan Medical University HospitalUniversità degli studi Magna Graecia di CatanzaroUniversity Hospital of GhentUniversiteit GentUniversidad Nacional Autónoma de MéxicoUniversidade Nova de LisboaRheumazentrum Ruhrgebiet St. Josefs-KrankenhausHospital Universitario La PazMarmara ÜniversitesiGuangzhou UniversityUniversity of California, San FranciscoHopital Cochin AP-HPNorth-Western State Medical University named after I.I. MechnikovUniversity of TorontoLeiden University Medical Center - LUMCMahidol UniversityUniversity of LeedsDunedin School of MedicineCairo UniversityMedizinische Universitat InnsbruckUniversity Hospital MaastrichtChonnam National UniversityUniversity of Zagreb School of MedicineMedical Park Gaziosmanpaşa Hospital2019-08-232019-08-232018-09-01Annals of the Rheumatic Diseases. Vol.77, No.9 (2018), 1311-131714682060000349672-s2.0-85049042058https://repository.li.mahidol.ac.th/handle/20.500.14594/45074© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. Objectives To evaluate construct validity, interpretability, reliability and responsiveness as well as determination of cut-off points for good and poor health within the original English version and the 18 translations of the disease-specific Assessment of Spondyloarthritis international Society Health Index (ASAS HI) in 23 countries worldwide in patients with spondyloarthritis (SpA). Methods A representative sample of patients with SpA fulfilling the ASAS classification criteria for axial (axSpA) or peripheral SpA was used. The construct validity of the ASAS HI was tested using Spearman correlation with several standard health outcomes for axSpA. Test-retest reliability was assessed by intraclass correlation coefficients (ICCs) in patients with stable disease (interval 4-7 days). In patients who required an escalation of therapy because of high disease activity, responsiveness was tested after 2-24weeks using standardised response mean (SRM). Results Among the 1548 patients, 64.9% were men, with a mean (SD) age 42.0 (13.4) years. Construct validity ranged from low (age: 0.10) to high (Bath AnkylosingSpondylitisFunctioning Index: 0.71). Internal consistency was high (Cronbach's α of 0.93). The reliability among 578 patients was good (ICC=0.87 (95% CI 0.84 to 0.89)). Responsiveness among 246 patients was moderate-large (SRM=-0.44 for non-steroidal anti-inflammatory drugs, -0.69 for conventional synthetic disease-modifying antirheumatic drug and -0.85 for tumour necrosis factor inhibitor). The smallest detectable change was 3.0. Values ≤5.0 have balanced specificity to distinguish good health as opposed to moderate health, and values ≥12.0 are specific to represent poor health as opposed to moderate health. Conclusions The ASAS HI proved to be valid, reliable and responsive. It can be used to evaluate the impact of SpA and its treatment on functioning and health. Furthermore, comparison of disease impact between populations is possible.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyImmunology and MicrobiologyMedicineArticleSCOPUS10.1136/annrheumdis-2017-212076